Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 11/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | LDHA | P00338 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7147740 | 0.84 | KIF11 (0.61) | KIF11KCNH2MEN1KMT2A | |
| SCHEMBL25713808 | 0.79 | KIF11 (0.51) | KIF11KCNH2PPARGPPARALDHA | |
| SCHEMBL19652449 | 0.79 | KIF11 (0.58) | KIF11KCNH2MEN1KMT2A | |
| SCHEMBL13247304 | 0.78 | KIF11 (0.74) | KIF11 | |
| SCHEMBL18053873 | 0.77 | KIF11 (0.52) | KIF11KCNH2MEN1KMT2ANPC1 | |
| SCHEMBL8457734 | 0.76 | KIF11 (0.54) | KIF11KCNH2PPARGPPARALDHA | |
| SCHEMBL2686112 | 0.76 | KIF11 (0.64) | KIF11KCNH2L3MBTL1 | |
| SCHEMBL8592606 | 0.75 | KIF11 (0.60) | KIF11KCNH2CES2CES1KMT2A | |
| SCHEMBL5838167 | 0.75 | KIF11 (0.60) | KIF11KCNH2CES2CES1KMT2A | |
| SCHEMBL7541631 | 0.75 | KIF11 (0.68) | KIF11KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781488-B2 | convergent assembly of a plurality of pairs of oligopeptides; stable C-terminal disulfide-protected carboxythioester group that can be deprotected to spontaneously generate a free C-terminal thioester; allows a single precursor to participate in a succession of chemical ligation reactions | AMYLIN PHARMACEUTICALS, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| EP-1529056-B1 | POST-CLEAVAGE SULFUR DEPROTECTION FOR CONVERGENT PROTEIN SYNTHESIS BY CHEMICAL LIGATION | AMYLIN PHARMACEUTICALS INC (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20070059792-A1 | convergent assembly of a plurality of pairs of oligopeptides; stable C-terminal disulfide-protected carboxythioester group that can be deprotected to spontaneously generate a free C-terminal thioester; allows a single precursor to participate in a succession of chemical ligation reactions | ASTRAZENECA PHARMACEUTICALS LP | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070059792-A1 | convergent assembly of a plurality of pairs of oligopeptides; stable C-terminal disulfide-protected carboxythioester group that can be deprotected to spontaneously generate a free C-terminal thioester; allows a single precursor to participate in a succession of chemical ligation reactions | NPEPPS, PCTP, PTMS | KIF11 3258/4885KCNH2 4547/4885PPARG 4746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.